Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

113
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
113
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

485
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
485
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

152
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
152
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

173
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
173
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

153
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
153
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

195
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
195

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Percutaneous Sclerotherapy for Giant Hepatic Haemangiomas: A New Paradigm in Australia.

ANZ journal of surgery·2026
Same author

Fatty Liver Disease in Australia: A Narrative Review on the Epidemiology, Natural History, Prognostication and Management in People With Metabolic Dysfunction.

The Medical journal of Australia·2026
Same author

Metabolic dysfunction-associated fatty liver disease: an update.

Australian prescriber·2026
Same author

The diagnosis and management of portal hypertension in cirrhosis: The Gastroenterological Society of Australia consensus.

Hepatology communications·2026
Same author

National survey of real-world treatment patterns for early- and intermediate-stage hepatocellular carcinoma reveals wide variation across Australian states.

Internal medicine journal·2026
Same author

Efficacy and Safety of Statins in MASLD and Other Chronic Liver Diseases.

Medical sciences (Basel, Switzerland)·2026

Related Experiment Video

Updated: Jul 19, 2025

Partial Bile Duct Ligation in the Mouse: A Controlled Model of Localized Obstructive Cholestasis
04:38

Partial Bile Duct Ligation in the Mouse: A Controlled Model of Localized Obstructive Cholestasis

Published on: March 28, 2018

15.7K

Current Therapeutics in Primary Sclerosing Cholangitis.

Natassia Tan1, John Lubel1, William Kemp1

  • 1Department of Gastroenterology and Hepatology, Alfred Health; Central Clinical School, Monash University, Melbourne, Australia.

Journal of Clinical and Translational Hepatology
|August 14, 2023
PubMed
Summary

Primary sclerosing cholangitis (PSC) is a rare liver disease with no cure. Emerging therapies target gut health, bile acids, and cancer risk, offering new hope for patients.

Keywords:
24-Norursodeoxycholic acidBile acidFarnesoid X receptor agonistsLiver transplantMicrobiomePrimary sclerosing cholangitis

More Related Videos

A Two-Step Method for Percutaneous Transhepatic Choledochoscopic Lithotomy
03:56

A Two-Step Method for Percutaneous Transhepatic Choledochoscopic Lithotomy

Published on: September 13, 2022

2.4K

Related Experiment Videos

Last Updated: Jul 19, 2025

Partial Bile Duct Ligation in the Mouse: A Controlled Model of Localized Obstructive Cholestasis
04:38

Partial Bile Duct Ligation in the Mouse: A Controlled Model of Localized Obstructive Cholestasis

Published on: March 28, 2018

15.7K
A Two-Step Method for Percutaneous Transhepatic Choledochoscopic Lithotomy
03:56

A Two-Step Method for Percutaneous Transhepatic Choledochoscopic Lithotomy

Published on: September 13, 2022

2.4K

Area of Science:

  • Hepatology
  • Gastroenterology
  • Immunology

Background:

  • Primary sclerosing cholangitis (PSC) is an orphan cholestatic liver disease characterized by inflammatory biliary strictures.
  • Pathophysiology involves immune dysregulation, gut dysbiosis, environmental factors, gut-liver crosstalk, and altered bile acid metabolism.
  • Current treatments lack efficacy in altering disease progression, with liver transplantation being the only option for end-stage disease.

Purpose of the Study:

  • To review the current understanding and emerging therapeutic strategies for Primary Sclerosing Cholangitis (PSC).
  • To highlight potential treatments addressing the underlying pathophysiology of PSC.
  • To discuss management options for complications and associated risks in PSC patients.

Main Methods:

  • Review of existing literature on PSC pathophysiology and treatment.
  • Analysis of current and investigational therapeutic approaches, including microbiome manipulation, bile acid modulation, and pharmacologic interventions.
  • Evaluation of strategies for managing PSC complications and associated malignancies.

Main Results:

  • Ursodeoxycholic acid shows limited efficacy, improving liver biochemistry but not survival outcomes.
  • Fecal microbiota transplantation and antibiotics show promise for gut microbiome manipulation.
  • Synthetic bile acids, nuclear receptor agonists, fibrates, statins, and aspirin demonstrate potential in clinical trials.

Conclusions:

  • No proven medical therapy currently alters PSC disease progression.
  • Emerging therapies targeting gut microbiome, bile acid metabolism, and cancer risk reduction show significant promise.
  • Endoscopic balloon dilatation is preferred over stenting for managing symptomatic strictures in PSC.